1. Home
  2. JMM vs CGTX Comparison

JMM vs CGTX Comparison

Compare JMM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JMM
  • CGTX
  • Stock Information
  • Founded
  • JMM 1988
  • CGTX 2007
  • Country
  • JMM United States
  • CGTX United States
  • Employees
  • JMM N/A
  • CGTX N/A
  • Industry
  • JMM Trusts Except Educational Religious and Charitable
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • JMM Finance
  • CGTX Health Care
  • Exchange
  • JMM Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • JMM 60.4M
  • CGTX 53.4M
  • IPO Year
  • JMM N/A
  • CGTX 2021
  • Fundamental
  • Price
  • JMM $6.30
  • CGTX $3.18
  • Analyst Decision
  • JMM
  • CGTX Strong Buy
  • Analyst Count
  • JMM 0
  • CGTX 3
  • Target Price
  • JMM N/A
  • CGTX $2.83
  • AVG Volume (30 Days)
  • JMM 16.1K
  • CGTX 10.9M
  • Earning Date
  • JMM 01-01-0001
  • CGTX 08-07-2025
  • Dividend Yield
  • JMM 5.44%
  • CGTX N/A
  • EPS Growth
  • JMM N/A
  • CGTX N/A
  • EPS
  • JMM N/A
  • CGTX N/A
  • Revenue
  • JMM N/A
  • CGTX N/A
  • Revenue This Year
  • JMM N/A
  • CGTX N/A
  • Revenue Next Year
  • JMM N/A
  • CGTX N/A
  • P/E Ratio
  • JMM N/A
  • CGTX N/A
  • Revenue Growth
  • JMM N/A
  • CGTX N/A
  • 52 Week Low
  • JMM $5.29
  • CGTX $0.22
  • 52 Week High
  • JMM $6.10
  • CGTX $3.83
  • Technical
  • Relative Strength Index (RSI)
  • JMM 47.83
  • CGTX 89.77
  • Support Level
  • JMM $6.25
  • CGTX $1.40
  • Resistance Level
  • JMM $6.40
  • CGTX $1.97
  • Average True Range (ATR)
  • JMM 0.10
  • CGTX 0.36
  • MACD
  • JMM -0.01
  • CGTX 0.20
  • Stochastic Oscillator
  • JMM 36.00
  • CGTX 79.87

About JMM Nuveen Multi-Market Income Fund (MA)

Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: